Amsbio has launched a comprehensive portfolio of over 30 independently developed and manufactured cytokines specifically validated for organoid culture applications. The range addresses growing demand from researchers working with stem cells and induced pluripotent stem cells (iPSCs) in development and disease modelling, precision medicine, toxicology studies, and regenerative medicine.

Characterised by high purity and consistency

The cytokine collection includes Activin A, BMP-4, EGF, FGF-4, FGF-10, FGFb, FGF8b, HGF, IGF1, Noggin, R-Spondin 1, Shh, and Wnt3a. Each product features endotoxin levels below 0.01 EU/μg, alongside high activity, purity, and lot-to-lot consistency – critical parameters for reproducible experimental outcomes.

Supplied as ready-to-use formulations, the cytokines enable straightforward implementation through simple protocols. The products are engineered to preserve structural and genetic characteristics of normal mammalian tissues whilst maintaining the heterogeneity of original tissue samples. High-quality organoids can typically be cultivated within 4–7 days using these reagents.

Validated across multiple organoid models

Amsbio has validated all cytokines through in vitro models spanning human tumour organoids, including pituitary adenoma and breast cancer organoids, human normal organoids such as iPSC-derived intestinal organoids, and mouse normal organoids including intestinal and pancreas models. This extensive validation ensures compatibility across diverse research applications.

The tailored design of these cytokines for organoid culture systems represents a focused approach to supporting the expanding role of three-dimensional cell culture models. As organoids become increasingly central to understanding tissue development, disease mechanisms, and therapeutic responses, reliable and well-characterised reagents provide essential infrastructure for advancing this research methodology.

The standardised formulations aim to enhance experimental reproducibility – a key consideration as organoid technology transitions from specialised research tool to broader laboratory adoption.

For more information, visit: https://www.amsbio.com

Digital issue: Please click here for more information